Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 4, 1998, Pages 197-203

  Partin, A W ^a   Brawer, M K ^b   Subong, E N P ^a   Kelley, C A ^a   Cox, J L ^a   Bruzek, D J ^a   Pannek, J ^a   Meyer, G E ^b   Chan, D W ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Complexed PSA; Detection; Percent free PSA; Prospective; Prostate cancer

Indexed keywords

EID: 0001529952     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500232     Document Type: Article

References (18)

1. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update 1994. J Urol 1994; 152: 1358-1368.
2. Catalona WJ et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organconfined prostate cancer is increased through prostate-specific antigen based screening. JAMA 1993; 270: 948-954.
4. Stenman VH et al. A complex between prostate-specific antigen and α-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer. Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222.
5. Catalona WJ et al. Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-1220.
6. Luderer AA et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen. Urology 1995; 146: 187-194.
7. Partin AW et al. Analysis of percent free PSA for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996; 48: 55-61.
8. Vashi AR et al. Determination of the "reflex-range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
9. Thiel RP et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 1996; 48(6A): 45-50.
10. Marley GM et al. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology 1996; 48(6A): 16-22.
11. Reissigl A et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 1996; 48(6A): 62-66.
12. Wang TJ et al. Clinical utility of a complexed PSA immunoassay with a specific monoclonal antibody to PSA-ACT. J Urol 1997; 157(4): 147.
13. Catalona WJ et al. Use of percent free prostate specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: Results of a prospective multicenter clinical trial of 773 men. Submitted JAMA 1998.
14. Catalona WJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161.
15. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 1996; 48(6A): 33-39.
16. Chan DW et al. Clinical evaluation of two free PSA assays in combination with different total PSA assays. J Urol 1997; 157(Suppl): 112.
17. Fortunate A et al. fPSA/fPSA ratios obtained using nine commercial assays. Clin Chem 1996; 42(Suppl): 42.
18. Jung K et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem 1996; 42: 1026-1033.